ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
6 hedge funds and large institutions have $701K invested in ProShares UltraPro Short NASDAQ Biotechnology in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
35% less capital invested
Capital invested by funds: $1.07M → $701K (-$374K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $155K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$193K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$12.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$684 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$92.6K |
| 2 |
VF
Virtu Financial
New York
|
-$39.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$19.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $297K | -$19.7K | -1,357 | -6% |
|
|
2
Jane Street
New York
| $176K | +$193K | +13,247 | New |
|
|
VF
3
Virtu Financial
New York
| $169K | -$39.8K | -2,739 | -18% |
|
|
4
UBS Group
Zurich,
Switzerland
| $55K | +$12.6K | +869 | +27% |
|
|
5
Morgan Stanley
New York
| $3K | -$92.6K | -6,362 | -97% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $1K | +$684 | +47 | New |
|
ZBIO Hedge Fund Activity: Q1 2019 in Review
6 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q1 2019, worth a combined $701K — down 35% from $1.07M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ZBIO positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $193K. The largest seller was Morgan Stanley, cutting an estimated $92.6K.
- 6 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q1 2019, up from 4 in Q4 2018.
- Funds reported $701K of ProShares UltraPro Short NASDAQ Biotechnology stock for Q1 2019, down 35% quarter-over-quarter.
- 2 funds opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q1 2019 and 0 closed out, a net change of +2 holders.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q1 2019 was Jane Street, an estimated $193K added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q1 2019 was Morgan Stanley, an estimated $92.6K sold.
Based on aggregated 13F filings for Q1 2019.